BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//hacksw/handcal//NONSGML v1.0//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
ORGANIZER;CN=Arrowhead Pharmaceuticals Inc.:MAILTO:no-reply@mail.gcs-web.com
DTEND:20260530T040000Z
UID:85d992eb-6210-47a0-bf6c-e1295d970308
DTSTAMP:1778079348
LOCATION:https://ir.arrowheadpharma.com/events/event-details/european-association-study-liver-easl-2026-aro-inhbe-demonstrates-clinically
DESCRIPTION:Event Details https://ir.arrowheadpharma.com/events/event-details/european-association-study-liver-easl-2026-aro-inhbe-demonstrates-clinically
URL;VALUE=URI:https://ir.arrowheadpharma.com/events/event-details/european-association-study-liver-easl-2026-aro-inhbe-demonstrates-clinically
SUMMARY:Arrowhead Pharmaceuticals Inc. - European Association for the Study of the Liver (EASL 2026) – ARO‑INHBE demonstrates clinically meaningful reductions in liver fat as monotherapy and in combination with low-dose tirzepatide in adults with obesity
DTSTART:20260527T040000Z
END:VEVENT
END:VCALENDAR